drugset / Trial / NCT03929744
A Study of LY3502970 in Healthy Participants
RandomizedSequentialDouble-blindBasic science
Summary
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Timeline
- Start
- 2019-06-12
- Primary completion
- 2020-11-02
- Completion
- 2020-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |
| Subject | Midazolam | Small molecule | 200 ug | Oral |
| Subject | Orforglipron | Small molecule | 0.3 mg | Oral |
| Subject | Orforglipron | Small molecule | 1 mg | Oral |
| Subject | Orforglipron | Small molecule | 2 mg | Oral |
| Subject | Orforglipron | Small molecule | 3 mg | Oral |
| Subject | Orforglipron | Small molecule | 6 mg | Oral |
| Subject | Orforglipron | Small molecule | 16 mg | Oral |
| Subject | Orforglipron | Small molecule | 24 mg | Oral |
| Subject | Simvastatin | Small molecule | 20 mg | Oral |
Indications
No indication recorded.